PPD Earns 2010 Site Solutions Summit Eagle Award

Recognized for its strong relationships and collaboration with investigative sites

WILMINGTON, N.C.--(BUSINESS WIRE)-- PPD, Inc. (Nasdaq: PPDI) today announced it has been named the recipient of the 2010 Site Solutions Summit Eagle Award, recognizing the company as the most desirable contract research organization (CRO) with which to partner in an independent study of more than 300 experienced investigative sites.

This year’s award honored PPD and Eli Lilly and Company as the top contract research organization and pharmaceutical company, respectively, for their high level of professionalism, collaborative approach to relationships, ongoing support during clinical studies, payment terms and performance working with partner sites.

“We recognize the important role of sites in recruiting the right patients and delivering high quality data for our clients, and therefore we focus on building and maintaining strong, collaborative relationships with investigators,” said Martin Lee, M.D., vice president of site and patient recruitment for PPD. “This honor from such a prestigious group validates our efforts toward establishing highly professional relationships and supportive team environments with our sites.”

PPD received the award at the Site Solutions Summit Partnering for Success annual meeting of investigative sites, pharmaceutical companies and contract research organizations on Oct. 16, 2010, in Clearwater, Fla. The annual meeting is organized by RxTrials and the Association of Clinical Research Organizations.

The award follows PPD’s recognition earlier this year as one of the top two CROs in Europe in the 2010 CenterWatch European Site Survey.

PPD is a leading global contract research organization, celebrating 25 years of providing drug discovery, development and lifecycle management services. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 42 countries and more than 10,500 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help clients and partners accelerate the delivery of safe and effective therapeutics and maximize the returns on their R&D investments. For more information, visit www.ppdi.com.

Except for historical information, all of the statements, expectations and assumptions contained in this news release, including expectations and assumptions about PPD’s selection for the 2010 Site Solutions Summit Eagle Award, are forward-looking statements that involve a number of risks and uncertainties. Although PPD attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. In addition, other important factors which could cause results to differ materially include the following: the ability to attract and retain investigative sites; risks associated with and dependence on collaborative relationships; competition within the outsourcing industry; rapid technological advances that make our products and services less competitive; continued success in sales growth; loss of large contracts; increased cancellation rates; economic conditions and outsourcing trends in the pharmaceutical, biotechnology, medical device, academic and government industry segments; risks associated with acquisitions and investments, such as impairments; and the other risk factors set forth from time to time in the SEC filings for PPD, copies of which are available free of charge upon request from the PPD investor relations department.



CONTACT:

PPD, Inc.
Media:
Sue Ann Pentecost, 919-456-5890, [email protected]
Analysts/Investors:
Luke Heagle, 910-558-7585, [email protected]

KEYWORDS:   United States  North America  North Carolina

INDUSTRY KEYWORDS:   Health  Biotechnology  Cardiology  Clinical Trials  Medical Devices  Pharmaceutical  Research  Medical Supplies  Science

MEDIA:

Logo
 Logo

Suggested Articles

WuXi AppTec has appointed Celgene CAR-T program veteran David Chang to lead its cell and gene therapy CDMO, WuXi Advanced Therapies.

Maryland-based Emergent BioSolutions has won a $628 million contract with BARDA to manufacture targeted COVID-19 vaccine hopefuls.

About 76% remdesivir patients had at least one point of clinical improvement on a 7-point scale at day 11, versus 66% of patients on standard care.